Lubomir Sokol, MD
Hematology · Tampa, FLNPI 1376558957
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,749 of the $18,834 with a category attached, or 73.0%. 13 manufacturers reported payments, led by Kyowa Kirin, Inc. at 33.3% of the total. Reporting peaked in 2019 at $5,548 and has fallen 97.6% since, to $135 in 2025.
Across 29 payments — averaging $649.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$6K
- EUSA Pharma (US) LLC$5K
- Stemline Therapeutics Inc.$3K
- Daiichi Sankyo Inc.$2K
- Secura Bio, Inc.$2K
- AstraZeneca$157
- plus $518 from 7 others
Across 228 payments — averaging $7488.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin, Inc.$1.2M
- Eisai Inc.$365K
- Amgen$109K
- Kyowa Kirin Pharmaceutical Development, Inc$45K
- Pfizer$13K
What the payments were for
- Consulting fees$13,74973%
- Speaking & faculty fees$3,14017%
- Travel & lodging$6243%
- Food & beverage$1,3107%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 6 | $6,271 |
| EUSA Pharma (US) LLC | 11 | $5,173 |
| Stemline Therapeutics Inc. | 1 | $3,120 |
| Daiichi Sankyo Inc. | 1 | $2,096 |
| Secura Bio, Inc. | 1 | $1,500 |
| AstraZeneca | 2 | $157 |
| Seagen Inc. | 1 | $139 |
| Pfizer | 1 | $129 |
| Lilly USA, LLC | 1 | $125 |
| Recordati_rare_diseases_inc. | 1 | $58 |
| Genmab U.S., Inc. | 1 | $30 |
| Pharmaessentia USA Corporation | 1 | $25 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,834 in reported general payments places this provider in the 75th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PegasysPeginterferon Alfa-2a | 16 | $70,000 |
Paid to pharmacies, not to this prescriber.
Other hematology in Tampa
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Doris HansenTampa$141K
- Melissa AlsinaTampa$64K
- Alan ListTampa$49K
- Michael JainTampa$48K
- Kamran DarabiTampa$6K
- Lia PerezTampa$3K
- Nima GhalehsariTampa$3K
- Elizabeth SagatysTampa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.